eLife (Apr 2023)

Pleiotropic effects of BAFF on the senescence-associated secretome and growth arrest

  • Martina Rossi,
  • Carlos Anerillas,
  • Maria Laura Idda,
  • Rachel Munk,
  • Chang Hoon Shin,
  • Stefano Donega,
  • Dimitrios Tsitsipatis,
  • Allison B Herman,
  • Jennifer L Martindale,
  • Xiaoling Yang,
  • Yulan Piao,
  • Krystyna Mazan-Mamczarz,
  • Jinshui Fan,
  • Luigi Ferrucci,
  • Peter F Johnson,
  • Supriyo De,
  • Kotb Abdelmohsen,
  • Myriam Gorospe

DOI
https://doi.org/10.7554/eLife.84238
Journal volume & issue
Vol. 12

Abstract

Read online

Senescent cells release a variety of cytokines, proteases, and growth factors collectively known as the senescence-associated secretory phenotype (SASP). Sustained SASP contributes to a pattern of chronic inflammation associated with aging and implicated in many age-related diseases. Here, we investigated the expression and function of the immunomodulatory cytokine BAFF (B-cell activating factor; encoded by the TNFSF13B gene), a SASP protein, in multiple senescence models. We first characterized BAFF production across different senescence paradigms, including senescent human diploid fibroblasts (WI-38, IMR-90) and monocytic leukemia cells (THP-1), and tissues of mice induced to undergo senescence. We then identified IRF1 (interferon regulatory factor 1) as a transcription factor required for promoting TNFSF13B mRNA transcription in senescence. We discovered that suppressing BAFF production decreased the senescent phenotype of both fibroblasts and monocyte-like cells, reducing IL6 secretion and SA-β-Gal staining. Importantly, however, the influence of BAFF on the senescence program was cell type-specific: in monocytes, BAFF promoted the early activation of NF-κB and general SASP secretion, while in fibroblasts, BAFF contributed to the production and function of TP53 (p53). We propose that BAFF is elevated across senescence models and is a potential target for senotherapy.

Keywords